European Commission Grants Conditional Marketing Authorization of TALVEY® (talquetamab) for Some Patients with Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/european-commission-approves-talvey-talquetemab-relapse-refractory-myeloma)